EASDelearning

We're a free knowledge hub for #diabetes healthcare professionals, bringing you news and research updates, plus a suite of world-class e-learning modules

[EASDelearning @EASDelearning]

In the latest episode of our Gamechangers video series, Professor John Buse talks about a paper that he thinks will transform the way we manage #diabetes in years to come.

More Gamechangers episodes: https://t.co/gA3KoHQUuc

[EASDelearning @EASDelearning]

When a country faces war or natural disaster, it will face unique challenges in caring for its population with diabetes.

Read our report from #EASD2023 on the challenges faced by people with #diabetes in Yemen, Iraq and Syria.

👉 https://t.co/vCg74gmJon

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

We found a disruption to the seasonal pattern but no overall increase in the expected incidence of pediatric diabetes during the first three years of the COVID-19 pandemic in Ontario, Canada. @ADA_Pubs

Read Here➡️https://t.co/lEpgbHaFi4

[The Lancet @TheLancet]

People with diabetes often encounter stigma which can adversely affect their health.

In @TheLancetEndo, authors call on the health community to endorse an evidence-based pledge to proactively challenge, & bring an end to, diabetes stigma & discrimination. https://t.co/W8o8BLjmXY

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

These data define pathophysiological underpinnings of the tree structure, which has the potential to stratify #diabetes-related complications on the basis of routinely available variables & thereby expand the toolbox of precision diabetes diagnosis https://t.co/jEtx538vOj #T2D

[EASDelearning @EASDelearning]

5 things we don't yet know...about #diabetes

Take a look at our video series with leading researchers talking about the big research questions that still need to be answered.

👉 https://t.co/gSIGirLVBc

[Oscar Moreno # @moreno_perez_o]

🚨🚨🚨Real‐world effectiveness and safety of oral semaglutide in people living with T2D: A nationwide multicentre retrospective observational study (ENDO2S‐RWD) Diabetes, Obesity and Metabolism https://t.co/bHDtVbODpa 🆓 @sociedadSEEN @SENefrologia @secardiologia @SEMERGENap

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Psychosocial care for people with diabetic neuropathy needs attention from both clinicians and researchers: a call for action. @ADA_Pubs

Read Here➡️https://t.co/qCzdGjQvn7

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Both continuous and intermittently scanned continuous glucose monitoring provide significant reductions in HbA1c compared to usual care, with no adverse impact on hypoglycemia. @ADA_Pubs

Read Here➡️https://t.co/8EdCjkQFim

[EASDelearning @EASDelearning]

In our clip of the week, Professor John Buse discusses the paper that could change the future of screening for type 1 #diabetes. #T1D

Full clip on our site: https://t.co/BgtOkGFzJj

[Prof. Wasim Hanif @docwas]

Our paper Inequalities the management of diabetic kidney disease in UK primary care: A cross‐sectional analysis of a large primary care database - ⁦@idasgupta7⁩ ⁦@Nirantharakumar⁩ ⁦@sribellary⁩ ⁦@m_alikaramat⁩ ⁦@hazlehurst_j⁩ https://t.co/RiVia01Vna

[EASDelearning @EASDelearning]

When a country faces war or natural disaster, it will face unique challenges in caring for its population with diabetes.

Read our report from #EASD2023 on the challenges faced by people with #diabetes in Yemen, Iraq and Syria 👉 https://t.co/vCg74gnhdV

[Diabetologia @DiabetologiaJnl]

#GLP1ReceptorAgonists are associated with lower incidences of adverse cardiovascular events and all-cause mortality in individuals with #NAFLD and #type2diabetes, compared with other glucose-lowering medications @DrAKrishnanMD #matchedcohortstudy https://t.co/qKSF4v9MZi 🔓

[Diabetologia @DiabetologiaJnl]

Everything you need when designing a study to investigate hepatic glucose uptake with FDG PET: getting us one step closer to unravelling the relationship between #diabetes and liver glucose metabolism https://t.co/35qRddslht

[Prof Kamlesh Khunti @kamleshkhunti]

Meta-analysis 54 RCTs & 32 cohort studies

SGLT2 inhibitors significantly ⬇️ MI incidence in RCTs & cohort studies

Cardioprotective effects of SGLT2 inhibitors observed in people with and without a history of CVD.

Interesting forest plots!

https://t.co/fmvcHJIb2X

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

‘A blog to show case 10 folks or groups who –in my opinion-deserve a mention for their work which has helped many with #Diabetes through the year’

The “Top 10” for 2023

Thank you from me for all the work you all continue to do in challenging times

Link:
https://t.co/g3IlHYktUp

[Filip K. Knop @Filip_Knop]

Here, the brilliant Patrik Rorsman and team from @ocdem, @SahlgrenskaAcad and @OxfordBRC show the GLP-1 derivative GLP-1(9–36) to possess a direct inhibitory effect on glucagon secretion - an effect that was lost in alpha cells from human donors with #T2D

https://t.co/MNFOmL680z

[EASDelearning @EASDelearning]

Clip of the week: Professor John Buse chooses a gamechanging paper that he thinks will transform the way we manage #diabetes in years to come.

Full clip: https://t.co/BgtOkGG7yR

[Dr Amar Puttanna 🎸 @AmarPut]

Risk Factors for Young-Onset Dementia in the UK Biobank

15 risk factors identified, yep diabetes in there 😉 but a few interesting ones & considerations

@kamleshkhunti @scelee1 @ketandhatariya @EASDelearning @AskDrShashank @GoggleDocs @GeriSoc

https://t.co/RHIen70903

[EASDelearning @EASDelearning]

New findings from SURPASS were presented at #EASD2023, revealing that tirzepatide comes with some extra benefits. #Diabetes

Read our report: https://t.co/g8GNSPUYrP